Prosthetic Heart Valve Market By Product Type (Mechanical Heart Valves; Bioprosthetic (Tissue) Heart Valves; Stented Tissue Valves; Stentless Tissue Valves; Transcatheter Heart Valves (TAVR/TAVI)); By Valve Position (Aortic Valve Replacement (AVR); Mitral Valve Replacement (MVR); Pulmonary Valve Replacement (PVR); Tricuspid Valve Replacement (TVR)); By Material Type (Titanium & Carbon-based Mechanical Valves; Porcine Tissue Valves; Bovine Pericardial Tissue Valves; Homografts (Allografts) & Autografts); By End-User (Hospitals; Cardiac Centers; Ambulatory Surgical Centers (ASCs)); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Prosthetic Heart Valve Market Size & Overview

The prosthetic heart valve market was valued at $8.5 billion in 2024 and is projected to reach $15.2 billion by 2030, expanding at a CAGR of 10.2%. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, particularly heart valve disorders, among aging populations worldwide. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, responsible for approximately 31% of all global deaths, with a significant portion attributed to heart valve diseases, including aortic stenosis and mitral valve regurgitation. As the global population continues to age, the demand for heart valve replacement procedures, such as transcatheter aortic valve replacement (TAVR) & traditional open-heart surgery, is expected to rise substantially.

 

The market is also supported by technological advancements in prosthetic valve designs, including mechanical valves, bioprosthetic (tissue) valves, and newer innovations like transcatheter heart valves (TAVR/TAVI). These advancements are enabling more patients, including those considered high-risk or elderly, to undergo minimally invasive heart valve replacement procedures, improving clinical outcomes & reducing recovery times. The rising adoption of TAVR for low- and intermediate-risk patients is further propelling the market's growth, as this procedure offers a safer alternative to traditional surgery for many patients. Additionally, ongoing research & development in valve materials & designs, such as the use of advanced tissue engineering, will contribute to the market's expansion & improve long-term outcomes for patients.

 

Prosthetic Heart Valve Market Dynamics:

Market Drivers

Rising Prevalence of Valvular Heart Disease (VHD)

The increasing incidence of valvular heart diseases such as aortic stenosis and mitral regurgitation is a major driver of the prosthetic heart valve market. According to the American Heart Association (AHA), approximately 5 million Americans are diagnosed with moderate to severe valvular disease annually, with aortic stenosis affecting nearly 7% of individuals over 65. As global populations age, the demand for heart valve replacement procedures, including transcatheter & surgical valve replacements, is expected to grow significantly.

Technological Advancements in Prosthetic Valve Design

Innovations in prosthetic heart valve materials & designs are enhancing durability, hemodynamic performance & patient outcomes. Next-generation bioprosthetic valves feature anti-calcification treatments, extending valve longevity to over 15-20 years, reducing the need for repeat interventions. Additionally, polymer-based heart valves & tissue-engineered solutions are being explored as alternatives to traditional mechanical and bioprosthetic valves to improve biocompatibility and reduce thrombogenicity.

 

Market Restraints

High Procedural Costs & Limited Access in Emerging Markets

Prosthetic heart valve implantation, particularly TAVR, remains a costly procedure, with average costs ranging between $30,000 - $60,000 per procedure in the U.S. & Europe. In emerging economies, affordability and accessibility are further constrained due to limited reimbursement coverage & infrastructure gaps in cardiac centers. The high cost of advanced heart valves, including polymer-based & tissue-engineered valves, restricts their widespread adoption outside developed regions.

Durability Concerns & Risk of Valve Degeneration

Despite advancements, bioprosthetic heart valves have limited durability compared to mechanical valves, with an average lifespan of 10-15 years before degeneration occurs. Studies indicate that 20-30% of bioprosthetic valves require reintervention within 15 years due to calcification and structural deterioration. This is a key concern in younger patients (<60 years) who require lifelong valve function, often leading them to choose mechanical valves despite the need for lifelong anticoagulation therapy.

 

Market Opportunities

Advancements in Next-Generation Heart Valve Technologies

The development of polymer-based heart valves with enhanced thromboresistance & durability is creating new market opportunities. Companies are investing in nanotechnology-based coatings & bioengineered hybrid valves to overcome the limitations of traditional bioprosthetic & mechanical valves. Moreover, tissue-engineered heart valves (TEHV) are being explored for self-regeneration and personalized implants, offering promising long-term solutions, particularly for pediatric and young adult patients.

Increasing Adoption of Transcatheter Mitral & Tricuspid Valve Therapies

While TAVR dominates the transcatheter heart valve segment, transcatheter mitral valve repair (TMVR) and replacement (TMVR) are emerging as high-growth areas. The TMVR market is projected to grow at over 14% CAGR, driven by increasing approvals of MitraClip (Abbott) and other catheter-based mitral valve repair devices. Additionally, transcatheter tricuspid valve interventions are gaining traction, addressing an unmet need in tricuspid regurgitation (TR) treatment.

 

Prosthetic Heart Valve Market Segmentation: A Comprehensive Overview

By Product Type:

• Mechanical Heart Valves

• Bioprosthetic (Tissue) Heart Valves

• Stented Tissue Valves

• Stentless Tissue Valves

• Transcatheter Heart Valves (TAVR/TAVI)

 

By Valve Position:

• Aortic Valve Replacement (AVR)

• Mitral Valve Replacement (MVR)

• Pulmonary Valve Replacement (PVR)

• Tricuspid Valve Replacement (TVR)

 

By Material Type:

• Titanium & Carbon-based Mechanical Valves

• Porcine Tissue Valves

• Bovine Pericardial Tissue Valves

• Homografts (Allografts) & Autografts

 

By End User:

• Hospitals

• Cardiac Centers

• Ambulatory Surgical Centers (ASCs)

 

By Region:

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

 

Prosthetic Heart Valve Market Segment Analysis: Growth Trends Across Categories

By Product Type:

Leading Segment: Bioprosthetic (Tissue) Heart Valves

Bioprosthetic heart valves hold the largest market share in the prosthetic heart valve market, making up approximately 40-45% of the total market. The demand for bioprosthetic valves is driven by their ability to reduce the need for long-term anticoagulation therapy, making them a preferred choice for elderly patients or those with a contraindication to blood thinners. These valves are typically made from either porcine or bovine tissue, offering good durability & functionality.

Fastest-Growing Segment: Transcatheter Heart Valves (TAVR/TAVI)

Transcatheter heart valves (TAVR/TAVI) are the fastest-growing segment, with a projected CAGR of 12-14%. The significant growth in this segment is attributed to the increasing number of patients eligible for minimally invasive heart valve replacement procedures, particularly in older patients or those who are high-risk surgical candidates. As TAVR technology advances & becomes more accessible, its adoption rate is expected to continue rising rapidly.

 

By Valve Position:

Leading Segment: Aortic Valve Replacement (AVR)

Aortic valve replacement (AVR) is the leading valve position segment, capturing approximately 55-60% of the market share. The high demand for AVR procedures is driven by the growing prevalence of aortic stenosis, a condition that leads to narrowing of the aortic valve and is particularly common in elderly populations. The effectiveness of prosthetic heart valves in treating AVR has led to widespread adoption.

Fastest-Growing Segment: Mitral Valve Replacement (MVR)

Mitral valve replacement (MVR) is the fastest-growing segment with a CAGR of 9-11%. The growth is driven by the rising incidence of mitral valve diseases such as mitral regurgitation, along with advances in valve design and surgical techniques that are improving patient outcomes. Minimally invasive MVR procedures are contributing to the growing adoption of these valves.

 

By Material Type:

Leading Segment: Titanium & Carbon-based Mechanical Valves

Titanium & carbon-based mechanical valves are the leading material type, holding around 35-40% of the market share. These valves are known for their durability & longer lifespan, making them the preferred choice for younger patients who require a long-lasting valve replacement solution. They offer the advantage of not degenerating over time, which makes them suitable for lifelong use.

Fastest-Growing Segment: Bovine Pericardial Tissue Valves

Bovine pericardial tissue valves are the fastest-growing segment with a CAGR of 8-10%. These valves are gaining popularity due to their excellent hemodynamic performance & their ability to provide better outcomes compared to porcine tissue valves in certain patients. As the demand for tissue valves with improved durability grows, the use of bovine pericardial valves is expected to continue to rise.

 

By End User:

Leading Segment: Hospitals

Hospitals remain the largest end-user segment in the prosthetic heart valve market, accounting for approximately 65-70% of the total market share. The primary reason for this dominance is that hospitals are the main settings for complex heart surgeries, including valve replacement procedures, which require specialized medical equipment, expertise, and patient care.

Fastest-Growing Segment: Ambulatory Surgical Centers (ASCs)

Ambulatory surgical centers (ASCs) are the fastest-growing segment with a CAGR of 10-12%. The increase in minimally invasive surgeries and outpatient procedures for heart valve replacement, such as TAVR, is driving the growth of ASCs. These centers provide a more cost-effective & efficient alternative to traditional hospital settings, contributing to their rapid adoption.

 

By Region:

Leading Region: North America

North America holds the largest market share in the prosthetic heart valve market, capturing around 40-45% of the total market. The region benefits from a well-established healthcare infrastructure, high rates of heart disease, and a high adoption of advanced medical technologies. The United States, in particular, is the largest market for prosthetic heart valves, supported by a growing elderly population and a high volume of heart valve replacement procedures.

Fastest-Growing Region: Asia Pacific

The Asia Pacific region is the fastest-growing market for prosthetic heart valves, with a CAGR of 11-13%. This growth is attributed to the rising prevalence of cardiovascular diseases, improving healthcare infrastructure, and increased access to advanced medical treatments in countries such as China, India & Japan. As healthcare systems in these countries continue to evolve, the demand for heart valve replacement surgeries & prosthetic heart valves is expected to grow significantly.

 

Prosthetic Heart Valve Market Report Coverage

Report Attribute	Details
Forecast Period	2024 – 2032
Market Size Value in 2024	USD 8.5 Billion
Revenue Forecast in 2030	USD 15.2 Billion
Overall Growth Rate	CAGR of 10.2% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Valve Position, By Material Type, By End-User, By Geography
By Product Type	Mechanical Heart Valves; Bioprosthetic (Tissue) Heart Valves; Stented Tissue Valves; Stentless Tissue Valves; Transcatheter Heart Valves (TAVR/TAVI)
By Valve Position	Aortic Valve Replacement (AVR); Mitral Valve Replacement (MVR); Pulmonary Valve Replacement (PVR); Tricuspid Valve Replacement (TVR)
By Material Type	Titanium & Carbon-based Mechanical Valves; Porcine Tissue Valves; Bovine Pericardial Tissue Valves; Homografts (Allografts) & Autografts
By End-User	Hospitals; Cardiac Centers; Ambulatory Surgical Centers (ASCs)
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Increasing prevalence of valvular heart diseases, growing adoption of minimally invasive procedures (TAVR/TAVI), technological advancements in prosthetic heart valves, rising geriatric population
Pricing and Purchase Options	Customized options available

 

Key Players in the Prosthetic Heart Valve Market

• Medtronic plc

• Edwards Lifesciences Corporation

• Abbott Laboratories

• Boston Scientific Corporation

• Sorin Group (now part of LivaNova)

• JenaValve Technology

• CryoLife, Inc.

• Biomerics

• Labcor

• Neovasc Inc.

 

Recent Developments

• Medtronic plc (February 2025): Medtronic received FDA approval for its Hawk TAVR system, a new transcatheter aortic valve replacement (TAVR) device designed for patients with severe aortic stenosis. This approval expands Medtronic’s portfolio, offering a minimally invasive option for high-risk surgical patients, enhancing treatment options for aortic valve diseases.

• Edwards Lifesciences Corporation (November 2024): Edwards Lifesciences launched the SAPIEN 3 Ultra Transcatheter Heart Valve in Europe. This next-generation device offers enhanced durability & improved hemodynamic performance, particularly for patients with challenging anatomies, solidifying Edwards’ position as a leader in the TAVR market.

• Abbott Laboratories (January 2025): Abbott announced the successful completion of its EVOLUT PRO+ Transcatheter Valve Replacement clinical trial. The new valve is designed to improve procedural efficiency, particularly in patients with smaller or more complex aortic annuli, expanding the use of TAVR for a broader range of patients.

• Boston Scientific Corporation (December 2024): Boston Scientific acquired Baylis Medical, a move that will enhance its catheter-based products for TAVR procedures. The acquisition strengthens Boston Scientific's position in the heart valve market by providing complementary technology to its existing TAVR portfolio & expanding access to innovative cardiovascular solutions.

 

Future Outlook

The future outlook for the prosthetic heart valve market is highly optimistic, driven by ongoing advancements in valve design, minimally invasive procedures, and an aging global population. With the increasing prevalence of cardiovascular diseases, particularly in elderly populations, the demand for heart valve replacement procedures, including transcatheter aortic valve replacement (TAVR) and mitral valve repairs, is expected to continue growing. The market will benefit from innovations such as improved bioprosthetic valves, enhanced durability, and more precise, minimally invasive surgical techniques that reduce recovery time & improve patient outcomes. Additionally, the expansion of TAVR procedures to lower-risk patients and advancements in tissue-engineered valves will further propel market growth. Emerging economies, especially in Asia Pacific & Latin America, will contribute to significant growth, as these regions see improving healthcare infrastructure & increasing access to advanced cardiac treatments. As technology continues to evolve & the adoption of transcatheter valve therapies increases, the prosthetic heart valve market is poised to experience strong, sustained growth over the next decade.